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region with increased susceptibility of abdominal aortic
aneurysm in a Chinese Han population
Yingqi Wei, Jiang Xiong, Shangwei Zuo, Feng Chen, Dafang
Chen, Tao Wu, Wei Guo, Yonghua Hu
Objective: Several studies have reported that poly-
morphisms on chromosome 9p21.3, near the CDKN2A/2B
gene, are strongly associated with increased susceptibility
to abdominal aortic aneurysm (AAA). However, no con-
vincing data has been reported on a relationship between
AAA and these variants in the Chinese Han population. The
aim of this study was to evaluate the role of rs10757278
and rs1333049 in determining genetic susceptibility to
AAA.
Methods: A total of 155 AAA patients and 310 controls,
comparable in age and gender, were enrolled in this study.
DNA samples were genotyped for rs10757278 and
rs1333049 using the MassArray system. The association
between these two single nucleotide polymorphisms and
AAAs was tested using multivariate logistic regression.
Stratiﬁed analysis was also performed by clinical and labo-
ratory features.
Results: Single nucleotide polymorphisms rs10757278 and
rs1333049 were signiﬁcantly associated with increased risk
of AAA. The frequencies of rs10757278-G and rs1333049-C
in AAA patients were signiﬁcantly higher than in control
subjects (odds ratio [OR], 1.53; 95% conﬁdence interval [CI],
1.11-2.11; P = .01, and OR, 1.48; 95% CI, 1.07-2.05; P = .02).
Multiple logistic regression analysis indicated that, after
adjusting for smoking habits, drinking habits, and histories
of other chronic diseases, homozygosity of the risk allele for
rs10758278-G and rs1333049-C also increased the like-
lihood of AAA (OR, 2.31; 95% CI, 1.22-4.36, and OR, 2.14;
95% CI, 1.13-4.05). The frequency of the GC haplotype was
signiﬁcantly higher in AAA patients than in control subjects
(OR, 1.44; P = .038). Stratiﬁcation analysis of clinical and
laboratory features revealed no association between poly-
morphisms and aortic diameters in AAA patients. There was
a signiﬁcantly high frequency of the rs10757278 GG geno-
type in AAA patients with high serum total homocysteine
compared with those control subjects with high serum total
homocysteine (OR, 2.71; 95% CI, 1.12-6.58; P = .03) indi-
cating that the genotype GG of rs10757278 might interact
with the homocysteine biological pathway to stimulate the
presence of AAA.*Full articles available online at www.jvascsurg.org
1078-5884/$ e see front matter
http://dx.doi.org/10.1016/S1078-5884(14)00091-4Conclusions: Present data demonstrate that rs10757278
and rs1333049 on chromosome 9p21.3 are signiﬁcantly
associated with increased risk of AAA in the Chinese pop-
ulation and emphasize the need to further study the role of
these markers in AAA.A single center's ﬁrst 100 late endovascular aneurysm
repair explants
Eric J. Turney, Sean P. Steenberge, Sean P. Lyden, Matthew J.
Eagleton, Sunita D. Srivastava, Timur P. Sarac, Rebecca L.
Kelso, Daniel G. Clair
Objective: With more than a decade of use of endovascular
aneurysm repair (EVAR), we expect to see a rise in the
number of failing endografts. We review a single-center
experience with EVAR explants to identify patterns of pre-
sentation and understand operative outcomes that may
alter clinical management.
Methods: A retrospective analysis of EVARs requiring late
explants, >1 month after implant, was performed. Patient
demographics, type of graft, duration of implant, reason for
removal, operative technique, length of stay, complications,
and in-hospital and late mortality were reviewed.
Results: During 1999 to 2012, 100 patients (91% men)
required EVAR explant, of which 61 were placed at another
institution. The average age was 75 years (range, 50-
93years). The median length of time since implantation was
41 months (range, 1-144 months). Explanted grafts included
25 AneuRx (Medtronic, Minneapolis, Minn), 25 Excluder (W.
L. Gore & Associates, Flagstaff, Ariz), 17 Zenith (Cook
Medical, Bloomington, Ind), 15 Talent (Medtronic), 10
Ancure (Guidant, Indianapolis, Ind), 4 Powerlink (Endologix,
Irvine, Calif), 1 Endurant (Medtronic), 1 Quantum LP (Cor-
dis, Miami Lakes, Fla), 1 Aorta Uni Iliac Rupture Graft (Cook
Medical, Bloomington, Ind), and 1 homemade tube graft.
Overall 30-day mortality was 17%, with an elective case
mortality of 9.9%, nonelective case mortality of 37%, and
56% mortality for ruptures. Endoleak was the most common
indication for explant, with one or more endoleaks present
in 82% (type I, 40%; II, 30%; III, 22%; endotension, 6%;
multiple, 16%). Other reasons for explant included infection
(13%), acute thrombosis (4%), and claudication (1%). In the
ﬁrst 12 months, 23 patients required explants, with type I
endoleak (48%) and infection (35%) the most frequent
indication. Conversely, 22 patients required explants after 5
years, with type I (36%) and type III (32%) endoleak
responsible for most indications.
Conclusions: The rate of EVAR late explants has increased
during the past decade at our institution. Survival is higher
452 Abstractswhen the explant is done electively compared with emer-
gent repair. Difﬁculty in obtaining a seal at the initial EVAR
often leads to failure 1 year, whereas progression of
aneurysmal disease is the primary reason for failure >5
years.Dual antiplatelet therapy (clopidogrel and aspirin)
is associated with increased all-cause mortality after
carotid revascularization for asymptomatic carotid disease
Francisco Alcocer, Zdenek Novak, Bart R. Combs, Bruce
Lowman, Marc A. Passman, Marjan Mujib,William D. Jordan
Objective: Despite the established guidelines, there is not
a clear consensus about how to manage antiplatelet ther-
apy after carotid surgery. It is a common practice in vascular
surgery to use the combination of aspirin and clopidogrel in
the treatment of such patients. In this work, we analyzed
the impact on long-term survival of antiplatelet therapy in
patients treated for carotid stenosis at a single institution
over a 10-year period.
Methods: Outcomes of 471 patients who underwent ca-
rotid intervention (1999-2008) were analyzed. Discharge
prescription summaries were retrieved, and patients were
divided into two groups according to their antiplatelet
regimen: aspirin-only group and aspirin plus clopidogrel
group. Only patients with a minimum of 30 days of con-
ﬁrmed antiplatelet therapy were included. All-cause mor-
tality during follow-up represented the primary outcome,
whereas stroke and bleeding at 30 days and during follow-
up represented secondary end points. When local records
were sparse, the Social Security Death Index was queried to
conﬁrm mortality. The International Classiﬁcation of Dis-
eases, 9th Revision (ICD-9 codes), was reviewed for treat-
ment related to a bleeding condition.
Results: When divided by indication, there was an increased
mortality rate in patients with asymptomatic carotid disease
receiving dual antiplatelet therapy as compared with aspirin
alone (47% vs 40%; P = .05). Patients with symptomatic carotid
disease had a nonsigniﬁcant decrease in all-cause mortality if
they received dual antiplatelet therapy (38%vs39%;P = .53). In
a subgroup analysis, there was a signiﬁcant increase in the rate
of all-cause mortality among patients older than 75 years
receiving dual antiplatelet therapy for asymptomatic carotid
disease (82% vs 56%; P = .001), whereas there was a non-
signiﬁcant decrease inmortality in patients older than 75 years
receiving dual antiplatelet therapy for symptomatic carotid
disease (47% vs 63%; P = .50). There was no difference in
secondary outcomes (stroke and bleeding) regardless of the
indication or the antiplatelet therapy.
Conclusions: In this retrospective, single-institution study,
the use of dual antiplatelet therapy (aspirin plus clopidog-
rel) in patients intervened for asymptomatic carotid disease
was related to increased all-cause mortality, whereas it did
not signiﬁcantly inﬂuence the outcome in patients with
symptomatic carotid disease.Predictors and clinical signiﬁcance of progression or
regression of asymptomatic carotid stenosis
Stavros K. Kakkos, Andrew N. Nicolaides, Ioanna
Charalambous, Dafydd Thomas, Argyrios Giannopoulos, A.
Ross Naylor, George Geroulakos, Anne L. Abbott, for the
Asymptomatic Carotid Stenosis and Risk of Stroke (ACSRS)
Study Group
Objective: To determine baseline clinical and ultrasono-
graphic plaque factors predictive of progression or regres-
sion of asymptomatic carotid stenosis and the predictive
value of changes in stenosis severity on risk of ﬁrst ipsi-
lateral cerebral or retinal ischemic events (including stroke).
Methods: A total of 1121 patients with asymptomatic ca-
rotid stenosis of 50% to 99% in relation to the bulb diam-
eter (European Carotid Surgery Trial [ECST] method)
underwent six monthly clinical assessments and carotid
duplexes for up to 8 years (mean follow-up, 4 years). Pro-
gression or regression was considered present if there was
a change of at least one grade higher or lower, respectively,
persisting for at least two consecutive examinations.
Results: Regression occurred in 43 (3.8%), no change in 856
(76.4%), and progression in 222 (19.8%) patients.Younger age,
high grades of stenosis, absence of discrete white areas in the
plaque, and taking lipid lowering therapy were independent
baseline predictors of increased incidence of regression. High
serum creatinine, male gender, not taking lipid lowering
therapy, low grades of stenosis, and increased plaque area
were independent baseline predictors of progression.
One hundred and thirty ﬁrst ipsilateral cerebral or retinal
ischemic events, including 59 strokes, occurred. Forty
(67.8%) of the strokes occurred in patients whose stenosis
was unchanged, 19 (32.2%) in those with progression, and
zero in those with regression. For the entire cohort, the 8-
year cumulative ipsilateral cerebral ischemic stroke rate was
zero in patients with regression, 9% if the stenosis was
unchanged, and 16% if there was progression (average
annual stroke rates of 0%, 1.1%, and 2.0%, respectively; log-
rank, P = .05; relative risk in patients with progression, 1.92;
95% conﬁdence interval, 1.14-3.25).
For patientswith baseline stenosis 70% to99% in relation to
the distal internal carotid (North American Symptomatic Ca-
rotid Endarterectomy Trial [NASCET] method), in the absence
of progression (n = 349), the 8-year cumulative ipsilateral
cerebral ischemic stroke rate was 12%. In the presence of
progression (n = 77), it was 21% (average annual stroke rates
of 1.5% and 2.6%, respectively; log-rank, P = .34). Only nine
(30%) of the 30 strokes occurred in the progression group.
Conclusions: Progressive asymptomatic carotid stenosis
identiﬁed a subgroup with about twice the risk of ipsilateral
stroke compared with those without progression. However,
the clinical value of screening for progression simply for
selecting patients for carotid procedures is limited because
of the low frequency of progression and its relatively low
associated stroke rate. The cost effectiveness of screening
for change in stenosis severity to better direct current
optimal medical treatment needs testing.
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a multicenter trial with mandated ultrasound
surveillance
Lawrence Oresanya, Anil N. Makam, Michael Belkin, Greg-
ory L. Moneta, Michael S. Conte
Objective: Even in the setting of duplex ultrasound (DUS)
surveillance, a signiﬁcant number of lower extremity vein
bypass grafts (LEVBGs) become occluded as a ﬁrst event.
We sought to identify factors that may contribute to these
primary occlusions.
Methods: This was a retrospective analysis of the Project of
Ex Vivo Graft Engineering via Transfection III (PREVENT III)
multicenter randomized clinical trial, in which 1404 patients
with critical limb ischemia (CLI) underwent LEVBG with 1-
year follow-up. Subjects were to undergo DUS at regular
intervals (1, 3, 6, and 12 months), with reintervention
based on prespeciﬁed DUS criteria. Patients who had
nontechnical graft occlusion as the initial graft-related
event were identiﬁed, and multivariate analysis was used
to determine factors associated with primary graft
occlusion.
Results: Primary vein graft occlusion occurred in 200
subjects and accounted for 36% of all primary patency
events and 64% of all graft occlusions in the trial. Primary
occlusion events were evenly distributed throughout the
ﬁrst postoperative year. Rates of recurrent CLI, loss of
secondary patency, and major amputation in those with
primary occlusion were 55%, 79%, and 22% respectively as
compared to 18%, 10%, and 10% for subjects without
primary occlusion (P < .001). On multivariate analysis,
African-American race (subdistribution hazard ratio [SHR],
1.50; 95% conﬁdence interval [CI], 1.06-2.12), a graft
diameter <3 mm (SHR, 2.31; 95% CI, 1.33-4.01), and
nonadherence with ultrasound surveillance (SHR, 1.58;
95% CI, 1.10-2.27) were independently associated with
primary graft occlusion. Of the 123 subjects who received
their last scheduled surveillance DUS prior to a primary
occlusion event, 39 had a critical ultrasound abnormality
identiﬁed but failed to undergo graft revision, while 84 had
no critical ultrasound abnormality identiﬁed. Among these
84 subjects, female gender (SHR, 1.65; 95% CI, 1.07-2.54),
and graft diameter <3 mm (SHR, 2.12; 95% CI, 1.03-4.37)
were independent factors associated with unheralded graft
occlusion.
Conclusions: Among patients undergoing LEVBG for CLI,
almost half of primary patency events are occlusions
even in the setting of a DUS surveillance protocol. Af-
rican Americans, patients with smaller-diameter grafts,
and those who are nonadherent with surveillance ul-
trasound are at increased risk. Failure to intervene on
critical ﬁndings, and lack of sensitivity of DUS threshold
criteria to predict thrombosis, are also important con-
tributors. These ﬁndings suggest that prevention of vein
graft thrombosis requires further improvements in risk
stratiﬁcation, surveillance, and the timing of
reinterventions.Safety and feasibility of adjunctive dexamethasone
infusion into the adventitia of the femoropopliteal artery
following endovascular revascularization
Christopher D. Owens,Warren J. Gasper, Joy P.Walker, Hugh
F. Alley, Michael S. Conte, S. Marlene Grenon
Objective: Restenosis following endovascular treatment of
the femoropopliteal segment is associated with the in-
ﬂammatory response produced in the artery wall at the
time of the procedure. Although local drug delivery to the
superﬁcial femoral and popliteal arteries promises
improved patency, data are currently limited. We hypoth-
esized that improved percutaneous delivery of an anti-in-
ﬂammatory compound into the adventitia of the
femoropopliteal at the time of endovascular treatment
would be safe, feasible, and decrease the inﬂammatory
response.
Methods: This was a prospective, investigator-initiated,
phase I, ﬁrst-in-man study testing the safety and feasibility
of percutaneous adventitial delivery of dexamethasone.
Following successful intervention, an adventitial micro-
infusion catheter was advanced over a 0.014-inch wire to
the treated segment. Its microneedle (0.9 mm long x 140-
mm diameter) was deployed into the adventitia to deliver
dexamethasone (4 mg/mL) mixed with contrast agent
(80:20 ratio), providing ﬂuoroscopic visualization. The pri-
mary safety outcome measure was freedom from vessel
dissection, thrombosis, or extravasation while the primary
efﬁcacy outcome was duplex-determined binary restenosis
deﬁned as a peak systolic velocity ratio >2.5.
Results: Twenty patients with Rutherford clinical category
2-5 enrolled in this study. The mean age was 66, and 55%
had diabetes mellitus. Treated lesion length was 8.9 5.3
cm, and 50% were chronic total occlusions. Eighty percent
of treated lesions were in the distal superﬁcial femoral or
popliteal arteries. All lesions were treated by balloon an-
gioplasty with provisional stenting (n = 6) for suboptimal
result. Three patients were treated with atherectomy as
well. A mean of 1.6  1.1 mg (0.5  0.3 mL) of dex-
amethasone sodium phosphate was injected per centimeter
of lesion length. In total, a mean of 12.1 6.1 mg of dex-
amethasone was injected per patient. The mean number of
injections required per lesion was 3.0 1.3 cm, minimum
one and maximum six injections. There was 100% technical
success of drug delivery and no procedural or drug-related
adverse events. The mean Rutherford score decreased from
3.1  .7 (median, 3.0) preoperatively to .5  .7 at 6 months
(median, 0.0; P < .00001). Over this same time interval, the
index leg ankle-brachial index increased from .68  .15 to
.89  .19 (P = .0003). The preoperative C-reactive protein in
this study was 6.9  8.5 indicating severe baseline inﬂam-
mation, which increased to 14.0  23.1 mg/L (103%
increase) at 24 hours following the procedure. However, this
increase did not reach statistical signiﬁcance of P = .14. Two
patients met the primary efﬁcacy end point of loss of pri-
mary patency by re-occluding their treated segment of the
index lesion during the follow-up period.
454 AbstractsConclusions: Adventitial drug delivery via a microinfusion
catheter is a safe and feasible alternative to intimal-based
methods for adjunctive treatment in the femoropopliteal
segment. The 6-month preliminary results suggest peri-
vascular dexamethasone treatment may improve outcomes
following angioplasty to the femoral and popliteal arteries,
and support further clinical investigation of this approach.Diabetic women are poor responders to exercise
rehabilitation in the treatment of claudication
Andrew W. Gardner, Donald E. Parker, Polly S. Montgomery,
Steve M. Blevins
Background: It is not clear whether subgroups of patients
with peripheral artery disease (PAD) and claudication
respond more favorably to exercise rehabilitation than
others. We determined whether sex and diabetes were
factors associated with the response to exercise rehabil-
itation in patients with claudication.
Methods: Eighty patients were randomized to home-based
and supervised exercise programs, and 60 ﬁnished with
complete exercise intervention data. Exercise consisted of
intermittent walking to near maximal claudication pain for 3
months. Primary outcome measures included claudication
onset time (COT) and peak walking time. Patients were
partitioned into diabetic and nondiabetic groups and then
further partitioned by sex to form four groups.
Results: Overall, exercise adherence was high (84%), and
there was no signiﬁcant difference (P > .05) in the amount
of exercise completed among the four groups. All groups
had signiﬁcant improvements (P < .05) in COT and peak
walking time after exercise rehabilitation, except for dia-
betic women (P > .05). Only 37% of women with diabetes
had an increase in COT compared with 100% of men with
diabetes (P < .01), and their risk ratio for nonresponse was
9.2 (P < .0001).
Conclusions: Women with PAD and claudication, partic-
ularly those with diabetes, represent a vulnerable sub-
group of patients who respond poorly to a program of
exercise rehabilitation. Diabetic women with PAD and
claudication may need a greater dose of exercise or
another intervention separate from or in combination with
exercise to elicit improvements in claudication measures
that are similar to nondiabetic women and to diabetic and
nondiabetic men.A modern series of acute aortic occlusion
Jeffrey D. Crawford, Kenneth H. Perrone, Victor W. Wong,
Erica L. Mitchell, Amir F. Azarbal, Timothy K. Liem, Gregory
J. Landry, Gregory L. Moneta
Objective: Acute aortic occlusion (AAO) is a rare condition
associated with substantial morbidity and mortality. The
most recent large series was published over 15 years ago
and included patients from the 1980s. Previous studies
reported up to 50% of AAOs are caused by embolization,
with a mortality rate approaching 50%. We reviewed our
recent experience with AAOs to identify current etiologies
and outcomes in a contemporary series of patients with
AAOs.
Methods: Current Procedural Terminology codes and
data from a prospectively maintained vascular surgical
database were used to identify patients with acute oc-
clusion of the native aorta between 2005 and July 2013.
AAOs secondary to trauma, dissection, or graft occlusion
were excluded.
Results: We identiﬁed 29 patients with AAOs treated at our
institution. Twenty-three patients were transferred from
referring hospitals with a mean transfer time of 3.9 hours
(range, 0.5-7.5 hours). Twenty-two presented with occlusion
below the renal arteries and seven with occlusion extending
above the renal arteries. Resting motor/sensory lower ex-
tremity deﬁcits were noted in 17 patients. Eight patients
presented with complete paraplegia. Etiology was felt to be
aortoiliac thrombosis in 22 cases, embolic occlusion in 2,
and indeterminate in 5. Surgical revascularization was per-
formed in 26 cases (extra-anatomic bypass in 18, throm-
boembolectomy in 5, and aortobifemoral bypass in 3
patients. Three patients had no intervention. Acute renal
failure developed in 15 patients and rhabomyolysis in 10
patients. Fasciotomy was performed in 19 extremities. Nine
extremities were amputated in six patients. Overall mor-
tality was 34% with a 30-day mortality of 24% and a post-
procedure mortality of 15%.
Conclusions: AAO is an infrequent but devastating event.
The dominant etiology of AAOs is now thrombotic oc-
clusion. Despite advances in vascular surgery and critical
care over the past 2 decades, associated morbidity and
mortality remain substantial with high rates of limb loss,
acute renal failure, rhabdomyolysis, and death. Mortality
may be improved with expeditious extra-anatomic
bypass.
